Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes.

Interleukin-1 (IL-1), the main cytokine instigator of cartilage degeneration in arthritis, induces matrix metalloproteinase-3 (MMP-3) and MMP-13 RNA and protein in chondrocytes. The molecular mechanisms of this induction were investigated with specific inhibitors of mitogen-activated protein kinase (MAPK) signaling pathways and activating protein (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors. IL-1 rapidly induced the activation of extracellular-signal regulated kinase (ERK), protein 38 (p38) and c-Jun N-terminal kinase (JNK) MAPKs in the first-passage human femoral head OA chondrocytes. The ERK-MAPK pathway inhibitor, PD98059, attained 46-53% (MMP-3) and 59-66% (MMP-13) inhibition of RNA induction in human OA and 47-52% (MMP-3) and 69-73% (MMP-13) inhibition in bovine chondrocytes. U0126 conferred 37-77% (MMP-3) and 43-73% (MMP-13) suppression in human and 77-100% (MMP-3) and 96-100% (MMP-13) in bovine chondrocytes. P38 and JNK inhibitor, SB203580 caused 35-37% reduction of MMP-3 and MMP-13 RNA in human and 36-46% (MMP-3) and 60-88% (MMP-13) in bovine chondrocytes. Inhibitor of JNK, AP-1 and NF-kappa B, curcumin, achieved 48-99% suppression of MMP-3 and 45-97% of MMP-13 in human and 8-100% (MMP-3) and 32-100% (MMP-13) in bovine chondrocytes. NF-kappaB inhibitor, pyrrolidine dithiocarbamate yielded 83-84% reduction of MMP-3 and 38-55% for MMP-13 in human chondrocytes. In bovine chondrocytes, the induction decreased by 54-64% for MMP-3 and 74-93% for MMP-13 RNA. These results suggest the involvement of MAPKs, AP-1 and NF-kappa B transcription factors in the IL-1 induction of MMPs in chondrocytes. Inhibition of IL-1 signal transduction by these agents could be useful for reducing cartilage resorption by MMPs in arthritis.

[1]  W. B. Berg.  Arguments for interleukin 1 as a target in chronic arthritis. , 2000 .

[2]  John C. Lee,et al.  Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. , 1997, Journal of immunology.

[3]  R. Medford,et al.  Role of Activating Protein-1 in the Regulation of the Vascular Cell Adhesion Molecule-1 Gene Expression by Tumor Necrosis Factor-α* , 1998, The Journal of Biological Chemistry.

[4]  J. Pelletier,et al.  Interleukin-1beta-converting enzyme/caspase-1 in human osteoarthritic tissues: localization and role in the maturation of interleukin-1beta and interleukin-18. , 1999, Arthritis and rheumatism.

[5]  D. Brenner,et al.  Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. , 1999, Journal of immunology.

[6]  J. Martel-Pelletier,et al.  Elevated metalloproteinase and tissue inhibitor of metalloproteinase mRNA in human osteoarthritic synovia. , 1993, The Journal of rheumatology.

[7]  Qingbo Xu,et al.  Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[8]  C. Rorabeck,et al.  Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. , 1997, The Journal of clinical investigation.

[9]  J. Pelletier,et al.  Cloning, sequencing and characterization of the 5'-flanking region of the human collagenase-3 gene. , 1997, The Biochemical journal.

[10]  G. Firestein,et al.  Modulation of fibroblast-mediated cartilage degradation by articular chondrocytes in rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[11]  A. Cole,et al.  Expression of matrix metalloproteinases in normal and damaged articular cartilage from human knee and ankle joints. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[12]  J. Pelletier,et al.  The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. , 1992, Arthritis and rheumatism.

[13]  P. Dieppe,et al.  Susceptibility of normal and arthritic human articular cartilage to degradative stimuli. , 1992, British journal of rheumatology.

[14]  S. Santavirta,et al.  Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. , 1997, Arthritis and rheumatism.

[15]  A. Baker,et al.  Nuclear factor kappaB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. , 1999, Biochemical and biophysical research communications.

[16]  E. Vignon,et al.  Matrix metalloproteinase-13 expression in rabbit knee joint connective tissues: influence of maturation and response to injury. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[17]  M. Zafarullah,et al.  Thiol antioxidant, N-acetylcysteine, activates extracellular signal-regulated kinase signaling pathway in articular chondrocytes. , 2000, Biochemical and biophysical research communications.

[18]  M. Feldmann,et al.  Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  L. Joosten,et al.  IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. , 1999, Journal of immunology.

[20]  C. Westacott,et al.  Cytokines in osteoarthritis: mediators or markers of joint destruction? , 1996, Seminars in arthritis and rheumatism.

[21]  J. Pelletier,et al.  The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. , 1996, The Journal of clinical investigation.

[22]  D. Howell,et al.  Regulation of the rat interstitial collagenase promoter by IL‐1β, c‐Jun, and ras‐dependent signaling in growth plate chondrocytes , 1997, Journal of cellular biochemistry.

[23]  P. Roughley,et al.  Preferential mRNA expression of prostromelysin relative to procollagenase and in situ localization in human articular cartilage. , 1992, The Journal of clinical investigation.

[24]  P. Petrow,et al.  Characterization of collagenase 3 (matrix metalloproteinase 13) messenger RNA expression in the synovial membrane and synovial fibroblasts of patients with rheumatoid arthritis. , 1999, Arthritis and rheumatism.

[25]  K. Iwata,et al.  Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[26]  M. Malaise,et al.  Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. , 2000, The Journal of rheumatology.

[27]  J. Dayer,et al.  Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritis , 1995 .

[28]  J. Glowacki,et al.  Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes. , 1994, The Journal of clinical investigation.

[29]  F. Mehraban,et al.  Gene transfer of type 1 interleukin-1 receptor extracellular-domain complementary DNA into rabbit synovial cell line HIG-82 results in cellular blockade of interleukin-1 signal transduction. , 1998, Arthritis and rheumatism.

[30]  A. Manning,et al.  Jun N-terminal kinase in rheumatoid arthritis. , 1999, The Journal of pharmacology and experimental therapeutics.

[31]  A. Taniguchi,et al.  Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[32]  R. Gay,et al.  Anti-interleukin-1 and anti-CD44 interventions producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblasts. , 2000, Arthritis and rheumatism.

[33]  W. Ollier,et al.  High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis. , 2000, The Journal of rheumatology.

[34]  Giovanna Buttice,et al.  The AP-1 site is required for basal expression but is not necessary for TPA-response of the human stromelysin gene , 1991, Nucleic Acids Res..

[35]  T. Tan,et al.  Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin , 1998, Oncogene.

[36]  N. Bhardwaj,et al.  Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. , 1992, Arthritis and rheumatism.

[37]  Y. Okada,et al.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis , 2000, Annals of the rheumatic diseases.

[38]  P. Baeuerle,et al.  H2O2 and antioxidants have opposite effects on activation of NF‐kappa B and AP‐1 in intact cells: AP‐1 as secondary antioxidant‐responsive factor. , 1993, The EMBO journal.

[39]  A. Cole,et al.  Osteoarthritic lesions: involvement of three different collagenases. , 1997, Arthritis and rheumatism.

[40]  C. Brinckerhoff,et al.  Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. , 2000, Arthritis and rheumatism.

[41]  W. Feeser,et al.  The effects of IL-1 on mitogen-activated protein kinases in rabbit articular chondrocytes. , 1997, Biochemical and biophysical research communications.

[42]  M. Lotz,et al.  Selective activation of the mitogen-activated protein kinase subgroups c-Jun NH2 terminal kinase and p38 by IL-1 and TNF in human articular chondrocytes. , 1996, The Journal of clinical investigation.

[43]  R. Schleyerbach,et al.  Complexity of IL-1 beta induced gene expression pattern in human articular chondrocytes. , 1997, Osteoarthritis and cartilage.

[44]  D E Griswold,et al.  Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. , 1996, The Journal of pharmacology and experimental therapeutics.

[45]  F. Hobbs,et al.  Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.

[46]  A. Bridges,et al.  A synthetic inhibitor of the mitogen-activated protein kinase cascade. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. Woolley,et al.  Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. , 2001, Arthritis and rheumatism.

[48]  C. López-Otín,et al.  Structural analysis and promoter characterization of the human collagenase-3 gene (MMP13). , 1997, Genomics.

[49]  P. Roughley,et al.  Direct evidence for active metalloproteinases mediating matrix degradation in interleukin 1-stimulated human articular cartilage. , 1993, Matrix.

[50]  B. Aggarwal,et al.  Activation of Transcription Factor NF-κB Is Suppressed by Curcumin (Diferuloylmethane) (*) , 1995, The Journal of Biological Chemistry.

[51]  R. Maciewicz,et al.  Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. , 1996, The Journal of clinical investigation.

[52]  E. Lechman,et al.  Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis , 1999, Gene Therapy.

[53]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[54]  K. Geoghegan,et al.  Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. , 1996, The Journal of clinical investigation.

[55]  R. Heller,et al.  Cytokine Control of Interstitial Collagenase and Collagenase-3 Gene Expression in Human Chondrocytes* , 1996, The Journal of Biological Chemistry.

[56]  Jen-kun Lin,et al.  Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. Lark,et al.  In vivo expression of stromelysin in synovium and cartilage of rabbits injected intraarticularly with interleukin-1 beta. , 1992, Arthritis and rheumatism.